Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Catabasis Pharmaceuticals, Inc (NASDAQ: CATB).

Full DD Report for CATB

You must become a subscriber to view this report.


Recent News from (NASDAQ: CATB)

Key events next week - healthcare
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 10:12
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
Webinar at 1:00pm ET on November 7 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: “PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor, in Du...
Source: Business Wire
Date: November, 02 2018 08:00
Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13
The Company Will Host a Conference Call at 8:30am ET Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report third quarter 2018 financial results before the Nasdaq Global Market open on Tuesday, November 13, 2018. Jill C. Milne, Ph.D., ...
Source: Business Wire
Date: October, 30 2018 08:00
Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Catabasis Pharmaceutical...
Source: GlobeNewswire
Date: October, 18 2018 08:25
Catabasis Pharma up 6% premarket on edasalonexent data in DMD
Nano cap Catabasis Pharmaceuticals (NASDAQ: CATB ) is up  6%  premarket on modest volume on the heels of new data supporting the use of magnetic resonance imaging (MRI) T2 as a potential marker for clinical outcome in boys with Duchenne muscular dystrophy (DMD). The results were ...
Source: SeekingAlpha
Date: October, 03 2018 09:21
Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress
-- Data from Large Natural History Study Show Strong Correlation of Lower Leg Composite MRI T2 with DMD Disease Progression, Supporting Positive Edasalonexent Effects in the MoveDMD ® Trial -- -- Positive MoveDMD Clinical Results Through 72 Weeks of Edasalonexent Treatment an...
Source: Business Wire
Date: October, 03 2018 08:00
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy
-- Pivotal Study of Novel Inhibitor of NF-kB, a Key Driver of Skeletal Muscle Disease and Cardiomyopathy in Duchenne -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of PolarisDMD, the Company’s Phase...
Source: Business Wire
Date: September, 25 2018 08:00
Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress
-- Late Breaking Presentation of Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne – -- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmac...
Source: Business Wire
Date: September, 19 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-170.590.52110.59990.52553,358
2018-12-140.620.59570.62450.5704321,399
2018-12-130.610.6150.64990.6002295,725
2018-12-120.600.61990.6250.60287,511
2018-12-110.610.6270.630.57242,056

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-17106,402297,36035.7822Short
2018-12-1439,23669,49356.4604Short
2018-12-1334,110135,34825.2017Cover
2018-12-1214,465155,5879.2970Cover
2018-12-1123,06481,87828.1687Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CATB.


About Catabasis Pharmaceuticals, Inc (NASDAQ: CATB)

Logo for Catabasis Pharmaceuticals, Inc (NASDAQ: CATB)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $47,327,868 - 05/11/2018
  • Issue and Outstanding: 29,035,502 - 03/07/2018

 


Recent Filings from (NASDAQ: CATB)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: April, 04 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: CATB)

Daily Technical Chart for (NASDAQ: CATB)


Stay tuned for daily updates and more on (NASDAQ: CATB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CATB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CATB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CATB and does not buy, sell, or trade any shares of CATB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/